After Raising $13M, AI-Driven Protein Biotech Appoints Board Chair
ExpressionEdits, a biotechnology company leveraging AI and proprietary intronization technology to optimize protein expression, announced the appointment of Dr. Paul Bolno as Chair of its Board of Directors. Dr. Bolno, with over two decades of experience in biotech leadership, is known for his work as CEO of Wave Life Sciences, where he oversaw the company’s IPO in 2015 and the development of its RNA medicine platform, PRISM.
This announcement follows ExpressionEdits’ successful $13 million seed funding round in May 2024, co-led by Octopus Ventures and redalpine, with additional backing from prominent venture funds. The funding has supported the company’s development of its AI-powered Genetic Syntax Engine, a platform designed to optimize gene expression for protein-based therapeutics and gene therapies.
See also: From Gene Editing to Pathway Design: How AI is Transforming Synthetic Biology
Founded in 2021 at the University of Cambridge, ExpressionEdits utilizes its intronization technology to address challenges in manufacturing recombinant proteins and designing efficient gene therapies. The technology integrates biological data with AI to enhance protein expression levels while minimizing toxicity, enabling new possibilities in genetic medicine.
Dr. Kärt Tomberg, CEO of ExpressionEdits
“Dr. Bolno’s expertise in drug development and strategic leadership will be instrumental in accelerating our mission to advance genetic medicines.”
Dr. Paul Bolno, Chair of the Board of Directors
“The proprietary Genetic Syntax Engine has incredible capabilities beyond protein-based therapeutics, including in the field of gene therapies. For gene therapy, ExpressionEdits has the potential to boost potency and precision by creating in-cDNAs with optimal sites and introns, leading to increased protein production without altering core designs. I’m very excited about the future of this platform to solve big challenges in genetic medicines.”
Topics: Startups & Deals
